UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
| |
||
| (Address of principal executive offices) | (Zip Code) |
(Registrant’s telephone number, including area code):
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
Trading |
Name of each exchange | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 7.01 | Regulation FD Disclosure. |
On December 8, 2021, Minerva Neurosciences, Inc., or the Company, released a presentation of the Company’s product candidate roluperidone at the 60th Annual Meeting of the American College of Neuropsychopharmacology, taking place at the Puerto Rico Convention Center, San Juan, Puerto Rico.
A copy of the above-referenced presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information furnished pursuant to Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference into any of the Company’s filings under the Securities Act of 1933, as amended or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing. The furnishing of the information in this Current Report on Form 8-K is not intended to, and does not, constitute a determination or admission by the Company that the information in this Current Report on Form 8-K is material or complete, or that investors should consider this information before making an investment decision with respect to any security of the Company.
| Item 9.01 | Financial Statements and Exhibits |
| (d) | Exhibits |
| Exhibit No. |
Description | |
| 99.1 | Presentation of Minerva Neurosciences, Inc. dated December 8, 2021. | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). | |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| MINERVA NEUROSCIENCES, INC. | ||
| By: | /s/ Geoffrey Race | |
| Name: | Geoffrey Race | |
| Title: | President | |
Date: December 8, 2021
3 Authors: Michael Davidson1,2 MD, Jay Saoud1 PhD, Corinne Staner3 MD, Nadine Noel3 PhD, Sandra Werner3 PhD, Elisabeth Luthringer3 RN, Philip Harvey PhD, Gregory Strauss PhD, Mark Weiser4MD, Remy Luthringer1 PhD Efficacy and safety of roluperidone for the treatment of negative symptoms of schizophrenia Study registration: Eudra-CT: 2017-003333-29; NCT03397134 Affiliations: (1) Minerva Neurosciences; (2) Nicosia University Medical School; (3) PPRS, (4) University of Tel Aviv School of Medicine (6) University of Miami Miller School of Medicine (7) University of Georgia Minerva Neurosciences is the sponsor of the trials Exhibit 99.1
Abstract Objective: In a previous large multi-national trial, roluperidone (MIN-101) a compound with antagonistic properties for 5‑HT2A, sigma2 and α1A-adrenergic receptors demonstrated statistically significant efficacy in reducing negative symptoms and good tolerability in stable schizophrenia patients. The objective of the current study was to confirm roluperidone’s efficacy, safety, and tolerability in similar schizophrenia patients. Methods: Roluperidone 32 mg/day, roluperidone 64 mg/day, or placebo was administered for 12 weeks to 513 schizophrenia patients with moderate to severe negative symptoms. The primary endpoint was the PANSS-derived Negative Symptoms Factor Score (NSFS) (Marder negative symptoms subscore) and the key secondary endpoint was Personal and Social Performance scale (PSP) total score. Results. NSFS scores were lower (improved) for roluperidone 64 mg compared to placebo and marginally missing statistical significance for the intent-to-treat (ITT) analysis set (p ≤0.064) but reaching nominal significance (p ≤0.044) for the modified-ITT (mITT)* set. Change in PSP total score was significantly higher (better) on roluperidone 64 mg compared to placebo for ITT and mITT (p≥ 0.021 and p≥ 0.017, respectively). Conclusions: Results of this trial confirm roluperidone’s potential for the treatment of negative symptoms of schizophrenia leading to better daily functioning. * Modified ITT excluded 17/513 patients before the data lock and unblinding because of behavioural and physiologic implausible data
Roluperidone
Trial design and patient population 12 weeks double blind 32 mg/day, 64 mg/day or placebo in 1/1/1 ratio, followed by 9 months open label phase DSM-5 schizophrenia Baseline score ≥ 20 on the PANSS negative symptoms subscale Symptomatically stable for 6 months A score <4 on the PANSS P-4excitement/hyperactivity P-6suspiciousness/persecution P-7hostility G-8uncooperativeness G-14 poor impulse control Upper threshold based on agitation/hostility rather than psychosis
Improvement
NSFS Score – Double-Blind Primary Endpoint , mITT Improvement Decision to exclude one site because of questionable data quality was taken before the data blinding was removed
Improvement
Other key efficacy parameters The relapse rate during the OLE, defined as patients being withdrawn from the trial due to worsening of symptoms of psychosis, was 15 patients out of 166 patients (9%) in the 32 mg arm and 10 patients out of 167 patients (6%) in the 64 mg arm. Over the one-year duration the relapse rate was 11.7% overall. CGI-S PANSS Total Score PANSS Positive Symptoms Score Reduced Emotional Experience Score
Phase 2b study showed improvements in NS over 12 weeks and 36 weeks in both doses and stable positive symptoms Core 12-week phase: Statistically significant improvements in the primary endpoint 12-Week DB & 24-week extension phase Core Phase Extension Phase Source: Davidson et al., 2017
Roluperidone showing improvement in both “Experience” & “Expression” of Negative Symptoms These results are consistent with improvements observed in other scales such as PSP (Personal & Social Performance Scale)
How much does the assessment instrument matter?
Discussion Roluperidone administered as monotherapy may improve negative symptoms and social functioning in patients suffering from schizophrenia and moderate to severe negative symptoms. Monotherapy, rather than add-on to antipsychotics, design was selected for two trials because: antipsychotics may produce secondary negative symptoms such as rigidity, akathisia and sedation hence confounding the effects of the experimental compound antipsychotics by blocking DA receptors and interfering with brain reward circuits, might enhance negative symptoms It is possible that a subgroup of patients with stable positive symptoms, low level of symptoms related to agitation and moderate to severe negative symptoms can maintain symptomatic stability in absence of maintenance treatment with antipsychotic drugs